Umibecestat (CNP520) is a beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor with IC 50 s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimers disease.
性状
Solid
IC50 & Target[1][2]
IC50: 11 nM (human BACE-1), 10 nM (mouse BACE-1)
体外研究(In Vitro)
Umibecestat (CNP520) is a potent BACE-1 inhibitor that is selective for BACE-1 over other human pepsin-like aspartic proteases, including BACE-2 and cathepsin D. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Umibecestat (CNP520) (1.5-51.3 mg/kg; given by oral gavage; 72 hours) shows a dose-dependent effects on Aβ40 and a long duration of action in both rat brain and CSF.
Umibecestat (CNP520) (3.1 mg/kg; oral administration; 7 days) shows a > 75% reduction on Aβ40 and Aβ42 in CSF after dosing and returns slowly to baseline over the next 7 days. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
ClinicalTrial
参考文献
[1]. Neumann U, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimers disease. EMBO Mol Med. 2018 Nov;10(11). pii: e9316.
溶解度数据
In Vitro: DMSO : 100 mg/mL (194.63 mM; Need ultrasonic)配制储备液